DI-87

• Description:

  DI-87 is an orally active and selective deoxycytidine kinase (dCK) inhibitor with an EC50 of 10.2 nM. DI-87 has antitumor activity and is used in combination therapy against tumors expressing dCK[1].

• Product Name Alternative:

  TRE-515

• UNSPSC:

  12352005

• Target:

  DNA/RNA Synthesis

• Type:

  Reference compound

• Related Pathways:

  Cell Cycle/DNA Damage

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/di-87.html

• Purity:

  99.52

• Solubility:

  DMSO : 145 mg/mL (ultrasonic)

• Smiles:

  NC1=NC(S[C@@H](C2=C(C)SC(C3=CC=C(OC)C(OCCN4CCOCC4)=C3)=N2)C)=NC(N)=C1

• Molecular Formula:

  C23H30N6O3S2

• Molecular Weight:

  502.65

• References & Citations:

  [1]Soumya Poddar, et al. Development and Preclinical Pharmacology of a Novel dCK Inhibitor, DI-87. Biochem Pharmacol. 2020 Feb;172:113742.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Phase 1

• CAS Number:

  2107280-55-5